Cytokine dysregulation is a central driver of chronic inflammatory diseases such as multiple sclerosis (MS). Here, we sought to determine the characteristic cellular and cytokine polarization profile in patients with relapsing-remitting multiple sclerosis (RRMS) by high-dimensional single-cell mass cytometry (CyTOF). Using a combination of neural network-based representation learning algorithms, we identified an expanded T helper cell subset in patients with MS, characterized by the expression of granulocyte-macrophage colony-stimulating factor and the C-X-C chemokine receptor type 4. This cellular signature, which includes expression of very late antigen 4 in peripheral blood, was also enriched in the central nervous system of patients with relapsing-remitting multiple sclerosis. In independent validation cohorts, we confirmed that this cell population is increased in patients with MS compared with other inflammatory and non-inflammatory conditions. Lastly, we also found the population to be reduced under effective disease-modifying therapy, suggesting that the identified T cell profile represents a specific therapeutic target in MS.
M ultiple sclerosis (MS) is a chronic inflammatory disease characterized by periodic infiltration of blood-derived leukocytes into the central nervous system (CNS), leading to damage of neuronal connections and progressive disability 1 . Given the complexity of MS, there is a long-standing interest in identifying biomarkers and signatures from easily accessible liquid biopsy material (blood). Numerous immune cell types, including T, B, natural killer and myeloid cells, together with their associated cytokine production, have been implicated in the pathophysiology of MS [2] [3] [4] . More specifically, while reduced regulatory T cell function 5 and increased frequencies of type 1 T helper (T H 1) 6, 7 , T H 17 (ref. 8 ) and granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting effector T cells 9, 10 have been reported in MS, the precise contribution of the different T H subsets is still controversial. One reason for the lack of solid biomarkers in peripheral blood mononuclear cells (PBMCs) of patients with MS is likely to be the hypothesis-driven nature of the investigations, which are inherently limited in their overall resolution and thus may bias the investigation towards arbitrarily classified cell subsets and biomarkers. High-parametric single-cell analysis [11] [12] [13] combined with automated computational tools [14] [15] [16] [17] [18] now provides a unique opportunity to comprehensively describe the peripheral immune compartment of patients with autoimmune diseases in an unbiased manner 13, 19, 20 . Here, we deeply analyzed PBMC samples from independent cohorts of patients with MS by mass cytometry in conjunction with unsupervised neural network (FlowSOM) and supervised representation learning (CellCNN) approaches. This allowed the convergent identification of a specific T H cell signature in MS, characterized by the expression of GM-CSF, tumor necrosis factor (TNF), interferon gamma (IFN-γ), interleukin-2 (IL-2) and C-X-C chemokine receptor type 4 (CXCR4). Of note, here, we show that this signature is dramatically reduced on disease-modifying therapy-namely, dimethyl fumarate (DMF). Finally, we identify an enrichment of this signature population in the CNS of patients with MS, highlighting its potential contribution to MS pathophysiology.
Results

Algorithm-guided identification of cytokine-expressing leukocytes in MS.
To provide a comprehensive landscape of cytokine production patterns of peripheral immune cells from patients with MS, we collected PBMCs of a large cohort of healthy donors, non-inflammatory neurological disease controls (NINDCs) and patients with relapsing-remitting MS (RRMS) (clinical parameters are described in Supplementary Table 1) . PBMCs were briefly stimulated in an antigen-independent manner and analyzed for the protein expression of several lineage-, activation-and traffickingassociated surface markers, together with the simultaneous analysis of 12 cytokines with single-cell resolution (Supplementary  Table 2 ). To define the major immune lineages directly based on their high-dimensional expression pattern, we employed the powerful abilities of FlowSOM-an artificial neural networkbased algorithm 16, 21 . Specifically, FlowSOM-defined nodes were then manually annotated into CD4 + , CD8
Figs. 1a,b and 2a-c). Next, we compared the composition of peripheral immune cells between patients with RRMS and NINDCs (additional clinical groups are compared in Extended Data Figs. 1-6 and  Supplementary Tables 3-4) without finding significant differences in their respective frequencies across these sample groups ( Fig. 1c and Extended Data Fig. 2c ).
To determine whether functional properties of different leukocyte populations are altered in patients with MS, we assessed the production of a broad range of cytokines in individual leukocyte lineages, highlighting a complex pattern of cytokine co-expression across different immune cell subsets (Fig. 1d) . We then interrogated the influence of aging on cytokine production and found that while most of the analyzed cytokines show a positive correlation with age 22 , GM-CSF and IL-6 production by PBMCs display a negative trend (Extended Data Fig. 3a-c) .
In line with previous reports 23 , when comparing cytokine production patterns in patients with RRMS and NINDCs, we observed several signs of cytokine dysregulation ( Fig. 1e and Extended Data Fig. 2f ), including a trend towards increased production of IL-2 (P = 0.109; r = 0.20) and IFN-γ (P = 0.074; r = 0.23) by peripheral blood cells in patients with RRMS. More strikingly (r = 0.31), we observed increased GM-CSF production in the PBMCs of patients with RRMS (2.2 ± 0.2%; median ± s.e.m) compared with NINDCs (1.5 ± 0.1%; P = 0.014).
In an effort to identify an MS-specific signature in a hypothesisfree and thus more unbiased manner, we employed CellCNN-a representation learning approach specifically designed for the detection of rare, disease-associated subpopulations 18 . CellCNN robustly identified a small subset of cells over-represented in patients with RRMS versus NINDCs (Fig. 1f) . To better describe their composition, we superimposed the previously FlowSOM-defined conventional immune populations. We found that the CellCNN-identified signature was almost exclusively comprised of T H cells (Fig. 1g,h ) largely expressing TNF, IL-2 and GM-CSF, and partly IFN-γ (Fig. 1i) , with only a minor fraction of CD8 + T cells.
T H cell GM-CSF production is modulated in patients with MS.
Given the initial increase in total GM-CSF production and its unbiased identification by supervised machine learning, together with previous reports about its potential role in the pathogenesis of MS 9, 10, 24 , we further investigated whether MS-associated augmentation of GM-CSF expression can be ascribed to a specific immune cell lineage. To this end, we first established an overview of all GM-CSF-competent immune subsets ( Fig. 2a and Extended Data Fig. 4a- 
c). CD4
+ T cells constituted the largest fraction of peripheral GM-CSF-expressing leukocytes across our cohort, followed by natural killer cells and CD8 + T cells. γδ T cells and B cells contributed to a lesser extent to GM-CSF production, whereas we only detected minor fractions of GM-CSF + myeloid cells and natural killer T cells. On stratification for clinical groups, we found the contribution of T H cells to peripheral GM-CSF production to be substantially augmented in patients with RRMS versus NINDCs (P = 0.008; r = 0.34; Fig. 2b and Extended Data Fig. 4b ). Next, we evaluated whether MS-associated modulation affected the frequencies of GM-CSF-producing cells within each lineage ( Fig. 2c and Extended Data Fig. 4c ). The relative frequency of GM-CSF-producing cells was highest in natural killer cells, followed by γδ T cells, CD4 +
T cells, CD8
+ T cells and B cells. Importantly, T H cells represented the population with the most significant increase in MS-associated GM-CSF production (P = 0.001; r = 0.41). We also observed slightly increased GM-CSF expression by γδ T cells and a positive trend in B cells, but not in natural killer cells or CD8 + T cells. Taken together, T H cells emerge as the major contributor to GM-CSF production in the peripheral immune compartment of patients with MS.
GM-CSF-producing T H cells constitute a heterogeneous population. Next, we examined whether GM-CSF production by T H cells is restricted to a specific T H cell subset. FlowSOM nodes were used to separate CD4 + T cells further into naive, effector, effector memory and central memory cells (Fig. 2d,e and Extended Data Fig. 4d,e) . GM-CSF production was highest in the effector memory fraction, followed by effector, central memory and naive T H cells.
Further exploiting the high-dimensional data structure, we analyzed the co-production of 11 additional cytokines by GM-CSFexpressing T H cells ( Fig. 2f and Extended Data Fig. 4f ). The vast majority of GM-CSF-producing T H cells co-expressed TNF and IL-2, followed by IFN-γ, which was produced by approximately one-third of GM-CSF + T H cells. A noticeable proportion also coexpressed IL-3, IL-4, IL-6, IL-13 and IL-21. To a lesser extent, GM-CSF expression coincided with IL-22 and IL-17A, while there was virtually no overlap between IL-10 and GM-CSF expression (Fig. 2g) . Conversely, we also examined whether any cytokines were more likely to be co-produced with GM-CSF. IL-3-producing cells had the highest level of GM-CSF co-expression, followed by the type 2 cytokines IL-4 and IL-13, T H 17-associated cytokines such as IL-17A, IL-6 or IL-22, and the type 1 cytokine IFN-γ ( Fig. 2h and Extended Data Fig. 4g ).
Next, we employed FlowSOM node metaclusters to define several GM-CSF-competent T H subsets, including T H 1, T H 2, T H 17 and T H 22 cells, T follicular helper cells (T FH ; IL-21 expressing T H cells) and a subset not co-expressing any of the other lineage-defining cytokines (hereafter termed T H GM cells 25 ). We were also able to identify regulatory T H cells, which were not found within GM-CSF + cells (Fig. 2i ,j and Extended Data Fig. 4h-j) . Most GM-CSF + T H cells solely co-expressed TNF and IL-2. Furthermore, IFN-γ-expressing T H 1 cells constituted about one-third of GM-CSF-producing T H cells, followed by T H 2 cells. T H 17 and T FH subsets were also found to contribute, albeit to a lesser extent. Despite the fact that we did not find a major MS-associated modulation of GM-CSF production by other lineages besides T H cells, these cells contribute considerably to peripheral GM-CSF production (Extended Data Figs. 5 and 6). PBMCs from all sample groups were restimulated with phorbol 12-myristate 13-acetate/ionomycin and analyzed by mass cytometry. a, Neural network-guided definition of immune cell lineages. The t-SNE algorithm (20,000 cells, randomly selected from NINDCs (n = 31) and patients with RRMS (n = 31)) was used to depict different populations therein. FlowSOM-based immune cell populations are overlaid as a color dimension. NK, natural killer; NKT, natural killer T. b, Mean population expression levels of all markers used for t-SNE visualization and FlowSOM clustering. c, Frequencies of immune cell lineages in peripheral leukocytes between NINDCs (n = 31) and patients with RRMS (n = 31) (left), and as a fraction within the total cohort (right). d, t-SNE-based overview of cytokine + cells across NINDCs (n = 31) and patients with RRMS (n = 31). e, Frequencies of cytokine + cells within PBMCs between clinical groups. f, Cells identified by CellCNN across three independent runs (left), and the frequency of these cells in PBMCs between clinical groups (right). g, CellCNNselected signature cells (colored) are overlaid on a t-SNE visualization of the major immune cell lineages from all samples. h, Composition of signature cells, using FlowSOM-based lineage definitions, from NINDCs (n = 9) and patients with RRMS (n = 19). i, Frequencies of cytokine + cells within selected T H cells from NINDCs (n = 9) and patients with RRMS (n = 19). P values are based on two-tailed Mann-Whitney-Wilcoxon tests between groups. r values were calculated from the z-statistic of the Mann-Whitney-Wilcoxon test. Box plots depict the interquartile range (IQR), with a white horizontal line representing the median. Whiskers extend to the farthest data point within a maximum of 1.5× the IQR. Every point represents one individual.
The CellCNN-identified MS signature is characterized by effector memory T H expression of GM-CSF and CXCR4. As shown above, GM-CSF-producing T H cells constitute a tremendously heterogeneous population, and a more precise MS-associated cellular signature might be concealed within a particular subpopulation. For this reason, we further characterized the CellCNN-identified, MS-expanded T H cell signature and found it to mostly belong to the effector memory and central memory compartments (Fig. 3a,b) . Accordingly, MS-expanded T H cells can be mostly described as T H 1  and T H GM cells, while only minor contributions of T FH , T H 2 and  T H 22 were identified (Fig. 3c) .
To capture the full heterogeneity of T H -associated single-cell cytokine production and the trafficking receptor profile, we performed a two-dimensional, categorical t-SNE analysis 26 . Here, we found the CellCNN-identified population to be characterized by consistent surface expression of the chemokine receptor CXCR4 (Fig. 3d) . Fractions of these cells additionally expressed either CCR4, CCR6 or both receptors. Collectively, the production of a specific set of cytokines, including GM-CSF, IL-2 and TNF, in combination with surface expression of CXCR4 therefore specifically delineates a pathologically expanded T H cell subset in patients with MS ( Fig. 3e, 
f).
The T H signature is increased in MS compared with other noninflammatory and inflammatory conditions. To validate our findings, we next investigated the immune profile of an independent cohort of age-matched patients with MS (n = 12), healthy controls (HCs; n = 15), patients diagnosed with clinical isolated syndrome (CIS; n = 8), NINDCs (n = 14) and patients affected by other inflammatory diseases (inflammatory disease controls (IDCs); n = 9) (Supplementary Table 5 and Extended Data Fig. 7a,b) . To eliminate batch effects, PBMCs from all donors were live cell barcoded, stained and simultaneously acquired (Supplementary Table 2 ). Using the same data analysis workflow described above (Extended Data Fig. 8a-d) , we could confirm signs of cytokine dysregulation in different immune populations 24, [27] [28] [29] . We found higher frequencies of IL-2-expressing cytotoxic T cells (T C cells) in the MS group compared with HCs (P = 0.07) and IDCs (P = 0.02), and higher frequencies of IL-6-expressing T C cells compared with HCs (P = 0.01). We also found a trend towards increased GM-CSF production by CD8 + T cells in patients with MS. GM-CSF-expressing B cells were also significantly increased in patients with MS compared with HCs (P = 0.02), IDCs (P = 0.02) and NINDCs (P = 0.04), but their overall contribution to GM-CSF production is minimal. Focusing on the T H cell compartment, we confirmed a significantly increased production of IL-2 (P = 0.02), IFN-γ (P = 0.02) and GM-CSF (P = 0.02) in patients with MS compared with NINDCs and HCs, while TNF (P = 0.05), IFN-γ (P = 0.04), IL-2 (P = 0.01) and IL-10 (P = 0.01) were increased in patients with MS compared with IDCs (Extended Data Fig. 8e-i) .
After this confirmation of cytokine dysregulation in MS, we again employed CellCNN and found that the overlay of previously identified CellCNN filters to this new cohort recognized the same signature population to be enriched in the MS group compared with either HCs, NINDCs or IDCs (Fig. 4a,b and Extended Data Fig. 7c,d ). Of note, this signature was also found to be increased in the CIS group compared with the HC group. This population was augmented irrespective of the MS clinical stratification and it correlates with several parameters, most notably with higher albumin quotient, which indicates blood-brain barrier dysfunction (Extended Data Fig. 7c,d ). As expected, categorical t-distributed stochastic neighbor embedding (t-SNE) reduction highlighted the surface expression of CXCR4 and the characteristic cytokine profile of this population. A consistent fraction of the signature population also co-expresses very late antigen 4 (VLA4) on the surface, which is involved in T cell migration into the CNS and is currently an effective immune target in MS 30 ( Fig. 4c ).
To confirm our findings in a readily accessible, low-dimensional space, we limited in silico the parameterization of our results and translated it into a basic five-parameter scheme for the analysis of T H compartments (Fig. 4d) . The evaluation of the manually gated fraction of GM-CSF, IFN-γ, IL-2 and TNF co-producing T H cells that express CXCR4 shows a significant enrichment of this population in the MS group compared with HCs (P = 0.005), NINDCs (P = 0.002) and IDCs (P = 0.032; Fig. 4e) .
Finally, further validating the notion that patients with MS harbor a disease-specific cellular signature population, we used the frequency of our signature from the combined datasets to predict its MS-association via logistic regression (Fig. 4f) . We built a receiver operating characteristic (ROC) curve to control for the sensitivity and specificity of our model in characterizing our binary outcome (that is, diagnosis of MS versus other conditions). Our model provided good predictivity, distinguishing MS from other clinical con- power: 0.89). Interestingly, our predictor did not allow a clear-cut stratification of patients with CIS from those with MS (AUC: 0.53; CI = 0.23-0.83; power: 0.04), likely due to the similar pathophysiology of these two conditions (Fig. 4g) . Finally, we determined the cut-off threshold that yielded the best sensitivity and specificity of our predictor (signature frequency threshold = 1.906%; true positive rate = 0.917; false positive rate = 0.789), with a notable computed odds ratio associated with MS (odds ratio = 10.41). This analysis reinforces our previous findings and links the identified signature to a well-established molecular target in MS (namely, VLA4). Overall, our data suggest an enrichment of this population in the context of MS, while its relative frequency is lower in IDCs, and negligible in either HCs or NINDCs.
The MS signature population is decreased by disease-modifying therapy. To better understand the contribution of our signature to the disease pathophysiology, we next quantified its frequency within the peripheral compartment of patients with MS in a therapeutic setting. Oral DMF is an efficient immunomodulatory treatment currently used in RRMS 31, 32 . While known to provoke changes in the lymphocyte composition, its precise mechanism of action is still elusive [33] [34] [35] [36] . To translate our findings into a more accessible clinical setting for biomarker measurements, we collected and analyzed by conventional flow cytometry a cohort of PBMCs longitudinally obtained from patients with MS before the initiation of DMF treatment and at 1 year follow up (clinical information is included in Supplementary Table 6 and Fig. 5a ).
Adopting a similar analytical approach to that described above, we initially quantified the main immune populations in our samples. On stratification at the different time points, we observed a reduced frequency of T cells, and in particular of T C cells, after 1 year of treatment. We also observed an increased frequency of B cells in treated patients, while the overall frequency of T H , natural killer and myeloid cells remained unaffected (Fig. 5b) .
To specifically investigate the impact of DMF on our cell signature, we further interrogated the T H compartment. As previously reported 37 , memory T H cells were significantly reduced on DMF treatment, with a concomitant increase in the frequency of naive T H cells (Fig. 5c,d) . Regarding cytokine production, we observed a significant decrease in the frequencies of IFN-γ and GM-CSF-producing T H memory cells, while other cytokines were not significantly affected compared with baseline samples (Fig. 5e,f) . Most importantly, when we compared the frequency of the signature population identified above at the different time points, we observed an even stronger reduction of this population, both among T H cells and memory T H cells (Fig. 5e,g ). Collectively, while confirming previously reported effects of DMF on systemic leukocyte frequencies, these data clearly indicate, via an easily reproducible technique, a strong and unanticipated impact of DMF on the identified MS signature in peripheral blood, further suggesting a pathological contribution of this population to MS. Pathologically expanded T cells are found in the CNS of patients with MS. Our analysis allowed the identification of a diseaseassociated immune signature in peripheral blood-a compartment readily accessible for research and diagnosis. Given the expression of CXCR4 on the identified population, and the putative role of its ligand (that is, stromal cell-derived factor α (SDF1α)) in lymphocyte migration in MS 38, 39 , we investigated the migratory capacity of immune cells in a transwell assay towards a concentration gradient of SDF1α. T cells migrate significantly better towards SDF1α compared with other immune populations (Extended Data  Fig. 9a-c) . When analyzing the cytokine profile of migrated T cells, the identified MS signature population displayed a higher capacity to migrate towards SDF1α compared with memory T H cells (Extended Data Fig. 9d,e) .
To determine whether the identified signature is indeed equipped to egress into the CNS and be maintained there, we additionally investigated the composition and cytokine expression profile of paired cryopreserved cerebrospinal fluid (CSF) and PBMC samples (Supplementary Table 7 ) concurrently harvested from patients with RRMS (Fig. 6a,b and Supplementary Table 8 ). Quality control of the samples was performed for reproducibility (Extended Data Fig. 10a,b) . In line with previous reports 40, 41 , we found higher frequencies of T H cells in the CSF of patients compared with their peripheral blood, while the frequencies of all other identified populations were decreased accordingly (Fig. 6c) . Since CSF cells recapitulate important characteristics of intrathecal inflammation, we next interrogated the cytokine expression profile of the identified T H cells. First, memory T H cells were increased in the CSF compartment compared with PBMCs, concurrent with the reduction of naive T H cells (Fig. 6d,e) . To circumvent any potential biases derived from the enrichment in antigen-experienced T H cells in the CSF, we focused our cytokine analysis exclusively on the memory compartment of PBMC-and CSF-derived T H cells. We observed a striking increase in TNF, IL-2, IFN-γ and GM-CSF production by T H cells in the CSF of patients with MS (Fig. 6f) . Importantly, no significant modification in the frequencies of IL-4-and IL-17-producing cells were observed between the two different compartments.
Next, we employed the Scaffold framework 42 to create a mass cytometry-based reference map of T H cells' heterogeneity (Extended Data Fig. 10c,d) . Using this approach, we successfully matched cells from our flow cytometry analysis to previously identified T H cell subsets, which allowed us to identify cells displaying the CellCNNbased MS signature within the CSF (Fig. 6g,h ). Importantly, this revealed a dramatic increase of MS signature cells within the CSF compared with the peripheral blood, with a proportional expansion within memory T H , total T H and overall immune cells (Fig. 6i) .
Finally, extending this analysis directly into inflamed CNS tissue, we investigated the expression of GM-CSF and CXCR4 on CD4
+ T cells at CNS inflammatory sites in autopsy samples of patients with MS not receiving immunomodulatory treatments. Immunofluorescence of CNS tissue samples confirmed the presence of CXCR4 + CD4 + T cells that co-produced GM-CSF in lesional sections from all patients with MS ( Fig. 6j and Extended Data Fig. 10e,f) . Altogether, this analysis underlined the definition of MS signature cells, showed that these cells are strongly enriched in the CSF of patients with MS and, furthermore, showed that they directly locate to sites of inflammation within the CNS.
Discussion
Here, we employed high-dimensional mass and flow cytometry in combination with two complementary and converging neural network-based learning approaches to identify a signature subpopulation of T H cells characterized by the expression of GM-CSF, TNF, IL-2 and CXCR4 in the peripheral blood and CSF of patients with RRMS. The majority of these cells also secrete IFN-γ, which together with GM-CSF has been shown to modulate myeloid cell function and potentially directly license these cells for tissue destruction [43] [44] [45] . Recently, compelling evidence from several studies highlighted GM-CSF to be especially central in MS pathophysiology . Besides T H cells, previous reports suggested a role for GM-CSF-producing CD8 + T cells 24 and B cells-the latter potentially explaining the efficacy of B cell depleting therapy in MS [27] [28] [29] . Apart from GM-CSF, other B cell-derived cytokines have been linked to MS as putative targets of B cell depleting therapy 51, 52 . However, several lines of evidence suggest an indirect role of B cells in supporting neuroinflammatory loops by antigen presentation, potentially promoting the survival and expansion of a T H -pathogenic repertoire 53 . Compared with previous studies, we exploited mass cytometry's high dimensionality to provide better coverage over immune population dynamics within the same experimental setting. To interrogate the immune profile of patients with MS, we further employed innovative algorithms for the automated identification of stratifying biomarkers (that is, CellCNN), devoid from previous assumptions. Even though we found a minor contribution of CD8 + T cells to the cellular signature in MS and increased GM-CSF production by B cells, our algorithmic approach primarily identified T H cells as the principal source of elevated GM-CSF production in MS.
Antigen specificity of T and B cell responses in MS remains a topic of debate, and thus far no uniquely responsible antigen has been identified. Reports of different T cell receptor avidities, interpatient variation and epitope spreading further complicate the topic 1 . Given this complexity, here, we focused on the antigenic history of patients by capturing cytokine activities in an antigen-independent manner across all major leukocyte populations. We discovered a potential link between disease-associated GM-CSF-producing T H cells and the chemokine receptor CXCR4, which has been shown to play an important role in regulating Peripheral blood and CSF cells, concurrently isolated from patients with MS (n = 9), were characterized by high-dimensional flow cytometry. a, The t-SNE algorithm (20,000 cells randomly selected) was used to depict the major immune populations in PBMC (n = 9) and CSF samples (n = 9). FlowSOM-based immune cell populations are overlaid as a color dimension. b, Mean population expression levels of the markers used for t-SNE visualization and FlowSOM clustering. c, Frequencies of immune cell lineages between paired PBMC (n = 9) and CSF samples (n = 9). d,e, Naive and memory T H cells were defined by exclusive CD45RA or CD45RO expression. Representative plots (d) and frequency quantifications (e) in the different compartments (n = 18) are shown. f, Frequencies of cytokine . Similarly, in our signature, we also observed high levels of VLA4, which is also a crucial modulator of immune cell migration in the CNS, and already a successful therapeutic target in MS therapy 30 . Supporting the notion that this population is equipped to egress into the CNS, we additionally analyzed paired CSF and peripheral blood samples of patients with MS, and we found the T H signature to be further increased in this CNS compartment. Other reports 
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have provided insights on cytokine production in the CSF of MS patients. We similarly observed an increased frequency of memory T cells that express GM-CSF and IFN-γ in this compartment compared with memory cells in the peripheral blood 9, 57 , while we did not detect increased frequencies of IL-17-expressing T H cells in the CSF, possibly due to our focus on antigen-experienced cells rather than on the bulk T H compartment 58 . Moreover, we also identified our T H signature within inflamed brain tissue of patients with MS, indicating that this population can cross the blood-brain barrier and infiltrate the CNS parenchyma, where it could either directly contribute to tissue damage or reinforce other inflammatory circuits.
While DMF treatment is known to provoke changes in the systemic lymphocyte composition, antigen-experienced T cells were identified as the most relevant population affected [33] [34] [35] [36] 59 . Using an easily accessible low-dimensional flow cytometric approach, here, we observed a strong decrease of the newly identified signature population in the blood of DMF-treated patients. Our analysis does not allow us to discern whether this reduction is, per se, responsible for the therapeutic effect of DMF rather than a consequence of reduced disease activity, and further studies are required to address this question by investigating the DMF-induced immune modulation of our identified signature in responding and non-responding MS patients. Similarly, the analysis of our model on broader, untreated cohorts of patients with neuroinflammatory disease is needed to better address the specificity of our MS signature.
Taken together, our results associate a specific T H cell population with a new molecular target, CXCR4, which potentially allows the egress of this pathological subset in the CNS of patients with MS. Since this population does not fall into classical T H categories, only pattern recognition allowed the identification of this unique and MS-specific T H signature. We believe that the precise characterization of GM-CSF + IL-2 + TNF + T H cells co-expressing the chemokine receptor CXCR4 provides new insights into disease etiology, and possibly offers both a diagnostic biomarker from an easily accessible compartment such as the peripheral blood and a novel therapeutic target to interfere with the aberrant immune dysregulation of MS without unspecific collateral immune suppression.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of code and data availability and associated accession codes are available at https://doi.org/10.1038/ s41591-019-0521-4. 60 , and healthy donors, as well as NINDCs, were defined according to the consensus definition guidelines 61 . Patients were classified as relapse if they presented with new neurological MS symptoms and/or magnetic resonance imaging displayed gadolinium-enhancing lesion(s) within 1 month before or after sampling. Systemic lupus erythematosus (SLE) was used as an inflammatory disease control with or without CNS involvement (CNS-SLE; defined as SLE with neuropsychiatric symptoms excluding tension headache, migraine and stroke). For flow cytometry analysis, RRMS was defined according to McDonald's revised diagnostic criteria for MS 62 . For the DMF cohort, cryopreserved PBMCs were collected longitudinally at the MS center of the University Hospital of Basel from individuals with RRMS diagnosed according to the 2011 revised McDonald criteria (see Supplementary Table 6 ). All donors had given written informed consent, and the study was approved by the Ethics Committee for Northwest/Central Switzerland (EKNZ 2014-48/12).
Isolation and cryopreservation of CSF cells. CSF samples (10 ml) were collected into 15-ml polypropylene tubes and centrifuged at 400 r.c.f. for 10 min at 4 °C. CSF supernatant (9 ml) was removed from collection tube. An equal volume of RPMI-1640 medium (PAN-Biotech) was added to the remaining CSF with cells, and held on ice until processing (within 1 h). CSF with media was centrifuged at 400 r.c.f. for 10 min at 4 °C to pellet the cells. The supernatant was discarded, CSF cell pellets were loosened and resuspended in 800 µl of human AB serum (SigmaAldrich). Cells were placed on ice and an equal volume of human AB serum with 20% dimethyl sulfoxide was added dropwise with gentle mixing. The CSF cell suspension was aliquoted into 2-ml cryotubes, placed in a CoolCell container and transferred to a −80 °C freezer for 12-72 h. Subsequently, CSF cells were transferred to a liquid nitrogen tank stored in the vapor phase.
Ex vivo reactivation of PBMCs and CSF cells.
Short-term reactivation of cryopreserved PBMCs and subsequent mass cytometry analysis were performed as described previously 19 . In short, PBMCs were kept in liquid nitrogen before thawing in a 37 °C water bath. Cells were resuspended in cell culture medium (RPMI-1640, 10% fetal calf serum (FCS; Biochrom), and 1× l-glutamine and 1× penicillin/streptomycin (both Life Technologies)) supplemented with 1:10,000 benzonase (Sigma-Aldrich), and centrifuged (300 r.c.f.; 7 min; 24 °C). Samples were then rested overnight at 37 °C before restimulation with 50 ng ml −1 phorbol 12-myristate 13-acetate (Sigma-Aldrich) and 500 ng ml −1 ionomycin (SigmaAldrich) in the presence of 1× Brefeldin A (BD Biosciences) for 4 h at 37 °C. Table 2 ) were purchased either preconjugated to heavy-metal isotopes (Fluidigm) or conjugated using the MaxPar X8 chelating polymer kit (Fluidigm). Flow cytometry antibodies were purchased preconjugated (Supplementary Table 8 ).
Antibodies. For mass cyometry, monoclonal anti-human antibodies (Supplementary
Live cell barcoding for mass cytometry. To minimize intersample staining variability, sample handling time and antibody consumption, we made use of a live cell barcoding approach 63 . In short, isothiocyanobenzyl-EDTA (Dojindo) was loaded with palladium isotopes ( Ta) , and conjugated to anti-human CD45 (BioLegend). 89Y-CD45 (Fluidigm) was used as an additional barcoding reagent. Samples were stained with anti-CD45 antibodies following reactivation at 37 °C for 25 min in cell staining medium (CSM; RPMI-1640 and 4% FCS) on a rotating shaker (500 r.p.m.), washed twice with CSM and combined into a single reaction vessel for further staining steps. Using this approach, up to 20 samples (equal ratio of patients with RRMS and controls) were combined and processed together. In total, multiple barcoding reactions were performed on three independent occasions. In our validation cohort, 73 samples were barcoded, combined and stained in one reaction vessel.
Surface staining. For mass cytometry, the barcoded and combined sample was resuspended in 400 μl of surface-antibody mixture (Supplementary Table 2 ) in CSM. Surface staining was performed for 20 min at 37 °C on a rotating shaker (500 r.p.m.). To identify dead cells, 2.5 μM cisplatin (Sigma-Aldrich) was added for 2 min on ice. For flow cytometry, 50 μl surface-antibody mixture (Supplementary Table 8 ) was added to the samples, followed by incubation for 30 min at room temperature.
Intracellular cytokine staining.
For mass cytometry, the combined surface-and live/dead-stained sample was fixed with 1.6% paraformaldehyde (PFA; Electron Microscopy Sciences) in phosphate buffered saline (PBS) for 30 min at 4 °C on a rotary shaker (500 r.p.m.). Fixed cells were washed twice with permeabilization buffer (PBS; 0.5% saponin, 2% bovine serum albumin and 0.01% sodium azide (all Sigma-Aldrich)). Cells were resuspended in 400 μl of intracellular antibody mixture (Supplementary Table 2 ) in permeabilization buffer for 1 h at 4 °C on a rotary shaker (500 r.p.m.). The sample was washed, supernatant was removed and the cells were resuspended in 1× iridium intercalator solution (Fluidigm) overnight. Lastly, the sample was washed twice with PBS/bovine serum albumin and once with double-distilled water before acquisition. For flow cytometry, similar fixation and permeabilization was performed. Cells were resuspended in 50 μl intracellular antibody mixture (Supplementary Table 8 ) in permeabilization buffer for 1 h at 4 °C on a rotatory shaker. Samples were then washed with CSM.
Acquisition and data preprocessing. Quality control and tuning of the CyTOF2 mass cytometer (Fluidigm) was performed daily. Acquisitions from different days (three independent acquisitions were performed) were normalized using five-element beads (Fluidigm) 65 . For downstream analysis, live, single cells were identified based on event length, DNA (   191   Ir and   193 Ir) and live cell ( 195 Pt) channels using FlowJo (TreeStar). The combined sample was debarcoded using MATLABbased software 64 . Flow cytometry samples were acquired on a FACSymphony system (BD Biosciences). Cytometry data from controls and patients with MS were transformed with an inverse hyperbolic sine (arcsinh) function (mass cytometry: cofactor of 5; flow cytometry: cofactor of 150) using the R environment 66 . To balance the influence of markers with different dynamic ranges, we performed background subtraction and channel-based percentile normalization using the 99.9th percentile of each marker across the whole barcoded dataset 15 . Individual cytokine positivity thresholds were determined based on the 0.99 percentile of the residual staining in an unstimulated control sample.
Algorithm-based high-dimensional analysis. Preprocessed data were downsampled to a maximum of 100,000 cells per donor. In the validation cohort, patients matching the ages of patients in the MS group (namely, subjects under 50 years of age) were considered for the analysis. All FlowSOM-based clustering was performed on the combined dataset to enable identification of small populations. For T H cells, resulting nodes were metaclustered with the indicated k-values (based on the elbow criterion) and annotated manually. The elbow point can be identified by examining the percentage of variance explained in relation to the number of clusters. Two-and one-dimensional t-SNE projections were calculated using the Rtsne package (perplexity = 50; theta = 0.1). CellCNN-based analysis was performed by training a randomly selected subset of cells. Default values were used for most CellCNN hyperparameters, except for the following: ncell = 2,000; scale = false; maxpool percentages = (0.5, 1.0, 2.5, 5.0, 10.0). Three independent subsamplings of 20,000 cells per donor were used to train the algorithm, and only the shared identified cells were used for subsequent analysis. Scaffold maps were created using the statistical Scaffold package 67 , with mass cytometry data as landmark nodes. All plots were drawn using ggplot2.
Migration assay. Cryopreserved PBMCs were thawed and rested overnight before they were used in a chemotaxis migration assay 68 . Briefly, cells were cultured in starvation medium (RPMI-1640; 1% FCS (Biochrom), and 1× l-glutamine and 1× penicillin/streptomycin (both Life Technologies) for 3 h and then loaded in the upper chamber for three additional hours in an incubator at 37 °C under 5% CO 2 . SDF1α was used at a concentration of 100 ng ml −1 in the upper, lower or upper and lower chambers of the transwell. Cells were then counted, restimulated for 4 h and stained as previously described, and acquired on a FACSymphony (BD Biosciences). Cell migration was calculated as a percentage of the specifically phenotyped input cell type.
Immunohistochemistry. MS brain tissues were obtained from the archives of the Institute of Neuropathology at the University Medical Centre Göttingen, Germany. The study was approved by the local ethics committee (numbers 14/5/03 and 29/9/10). Brain tissues from three autopsied patients with MS were analyzed. Tissues were cryosectioned (10-μm thick) for immunohistochemistry using a Hyrax C60 Cryostat (Zeiss) and stored at −80 °C. Brain sections were fixed in 2% PFA and acetone, washed in PBS, and blocked with PBS supplemented with 0.1% Triton X-100 and 4% normal goat serum. Subsequently, sections were incubated with the following primary antibodies (diluted in blocking solution) overnight at 4 °C: rat anti-GM-CSF antibody (BD Pharmingen; clone BVD2-21C11; 1:50); mouse anti-CD4 antibody (BioLegend; clone RPA-T4; 1:50) and rabbit anti-CXCR4 (Abcam; clone UMB2; 1:50). Sections were then washed in PBS and incubated with AF647-labeled goat anti-rat, AF488-labeled goat anti-mouse and AF555-labeled donkey anti-rabbit secondary antibodies (Life Technologies; 1:500) overnight at 4 °C or at room temperature for 1 h. Sections were mounted with SlowFade Gold Antifade reagent with DAPI (Invitrogen). Fluorescence photomicrographs were captured with a Leica SP5 Confocal Laser Scanning Microscope equipped with argon and helium lasers using the 40× objective (oil immersion; NA1.25). Images were processed and merged by Imaris imaging software (Bitplane).
Further immunohistochemistry stainings were performed as follow. Cryosections were incubated overnight in 4% PFA. For epitope demasking, sections were heated in a steamer with 10 mM citric acid buffer (pH 6.0), washed with bidistilled water and transferred to 0.3% H 2 O 2 in PBS for 10 min at 4 °C to block endogenous peroxidase. The sections were then washed with PBS and subsequently incubated with blocking buffer (10% FCS/PBS) for at least 20 min. Thereafter, the sections were prepared for primary and secondary antibody incubation. The following primary antibodies were used: mouse anti-BCAS1 antibody (Santa Cruz; sc-136342; 1:500), mouse anti-macrophage/activated microglia antibody (clone KiM1P; 1:5,000; a gift from H.-J. Radzun) and CD3 (DCS Innovative Diagnostic Systems; C1597CO1; 1:150). Antibody binding was visualized using biotinylated secondary antibodies (GE Healthcare, Jackson ImmunoResearch and DCS Innovative Diagnostic Systems), peroxidase-conjugated avidin and DAB (Sigma-Aldrich).
Statistical analysis. Frequencies of immune populations were compared with the non-parametric Mann-Whitney-Wilcoxon test using the R package coin. Parent populations with few cells were excluded from the statistical analysis. Controlling for multiple comparisons was accomplished with the Benjamini-Hochberg approach 69, 70 . Pearson's correlation coefficients (r) were calculated from the z-statistic of the Mann-Whitney-Wilcoxon test. The ROC predictivity and power (calculated as 1 − the false positive rate) analysis and odds ratio calculation were obtained using the pROC and oddsratio R package. The cut-off for odds ratio calculation was based on Youden's J statistical method 71 and also obtained using the oddsratio R package. For the CSF analysis, a paired Wilcoxon signed-rank test was used to compare different populations.
Study approval. All donors gave written informed consent and the study was approved by the regional ethical review board of Stockholm (PBMCs and CSF samples), Basel (PBMCs) and Göttingen (brain biopsies).
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
Mass cytometry and flow cytometry data analyzed in the manuscript (Figs. 1-6 ) are available in a public repository at http://flowrepository.org/experiments/2166/.
Patient-related data not included in the manuscript may be subject to patient confidentiality. Fig. 1 | Single-cell t-SNE profiling of immune cells. PBMCs from all sample groups were restimulated with phorbol 12-myristate 13-acetate (PMA)/ionomycin and analyzed by mass cytometry. The t-SNE algorithm (30,000 cells, equally selected from healthy donors (HDs; n = 29), NINDCs (n = 31) and patients with MS (n = 31) and from all samples) was used to depict different populations therein. a, The expression of each indicated marker is overlaid. b, FlowSOM-based immune cell populations are overlaid as a color dimension. Fig. 4 | Leukocyte and cytokine production characterization in subgroups of patients with MS. a, Exemplary GM-CSF production by total leukocytes with (right) or without (left) previous PMA/ionomycin stimulation (three independent experiments). b, Frequencies of immune cell lineages within GM-CSF + cells in NINDCs (n = 21), patients with RRMS during remission (n = 17) or during relapse (n = 10), patients with SPMS (n = 3) or PPMS (n = 2), and HDs (n = 24). c, Frequency of GM-CSF-positive cells in major immune lineages in NINDCs (n = 31), patients with RRMS during remission (n = 18) or during relapse (n = 12), patients with SPMS (n = 5) or PPMS (n = 3), and HDs (n = 29). d, Frequencies of FlowSOM-based T H memory subpopulations in total T H cells in NINDCs (n = 31), patients with RRMS during remission (n = 18) or during relapse (n = 12), patients with SPMS (n = 5) or PPMS (n = 3), and HDs (n = 29). e, Frequencies of GM-CSF + T H cells in NINDCs (n = 23), patients with RRMS during remission (n = 18) or during relapse (n = 11), patients with SPMS (n = 4) or PPMS (n = 3), and HDs (n = 27). f, Co-production of other cytokines by GM-CSF + T H cells in NINDCs (n = 23), patients with RRMS during remission (n = 18) or during relapse (n = 11), patients with SPMS (n = 4) or PPMS (n = 3), and HDs (n = 27). g, Frequencies of GM-CSF production by cytokine + T H cells in NINDCs (n = 13), patients with RRMS during remission (n = 14) or during relapse (n = 8), patients with SPMS (n = 4) or PPMS (n = 2), and HDs (n = 22). h, FlowSOM was used to identify total T H cell subsets based on their cytokine production profile (k = 17; elbow criterion). Clusters were manually annotated based on this profile. The mean expressions of surface and cytokine markers by the respective T H cell subsets are shown. i, Frequencies of FlowSOM-defined GM-CSF + T H cell subsets in NINDCs (n = 31), patients with RRMS during remission (n = 19) or during relapse (n = 12), patients with SPMS (n = 5) or PPMS (n = 3), and HDs (n = 29). j, The t-SNE algorithm (30,000 cytokine-expressing T H cells, equally selected from different clinical groups and from all samples) was used to depict different populations therein. FlowSOM-based T H subsets (left) and the expression of each indicated marker (right) are overlaid. Representation plots from randomly selected cells from three independent experiments are shown. Box plots depict the IQR, with a white horizontal line representing the median. Whiskers extend to the farthest data point within a maximum of 1.5× the IQR. Every point represents one individual. , IDCs (n = 9) and patients with CIS (n = 8) were restimulated with PMA/ionomycin and analyzed by mass cytometry. The t-SNE algorithm (20,000 cells randomly selected from all samples) was used to depict different populations therein. FlowSOM-based immune cell populations are overlaid as a color dimension. b, Mean population expression levels of all markers used for t-SNE visualization and FlowSOM clustering. c,d, Sample-specific (c) and frequencies of (d) immune cell lineages in peripheral leukocytes in patients with RRMS (n = 12), HCs (n = 15), NINDCs (n = 14), IDCs (n = 9) and patients with CIS (n = 8). e, Representative plot of cytokine staining in the unstimulated control (upper) and stimulated samples (lower). Cells randomly selected from the experimental run are shown. The positivity threshold was set on the residual staining, as described in the Methods. f-i, Frequencies of cytokine production by T H (f), T C (g), NK (h) and B cells (i) among patients with RRMS (n = 12), HCs (n = 15), NINDCs (n = 14), IDCs (n = 9) and patients with CIS (n = 8). Box plots depict the IQR, with a white horizontal line representing the median. Whiskers extend to the farthest data point within a maximum of 1.5× the IQR. Every point represents one individual. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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Methodology Sample preparation
Peripheral blood mononuclear cells and cerebrospinal fluid cells were used for cytometry experiment. Detailed protocols are reported in the Method section of the manuscript.
Instrument
CyTOF2, BD FACSymphony Software BD Diva software was used during data acquisition. Customized code used for data analysis will be uploaded in a GitHub repository before publication. Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
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